So lots of more and more studies are looking at and coming out with, um, you know, It's correlation with improved cognitive function as we age in the realm of Alzheimer's, dementia, it's neuroprotective [00:38:00] benefits from an inflammatory perspective, from a blood sugar, insulin perspective and again, You know, Alzheimer's dementia is a big, big medical burden in our country and is heavily tied in to blood sugar
Survodutide and retatrutide are investigational compounds not approved for human use
This makes access to this treatment more convenient for those seeking support in their weight loss journey
[5] [2] Patients starting GLP-1 therapy should be aware of: Potential mood changes during the adjustment period, particularly if experiencing significant gastrointestinal side effects The importance of continuing existing mental health treatments unless advised otherwise by their healthcare team Realistic expectations regarding weight loss and metabolic improvements, as unrealistic goals can lead to disappointment Healthcare professionals prescribing GLP-1 agonists should: Screen for depression and anxiety at baseline and during follow-up appointments Monitor for mood changes , particularly in patients with pre-existing mental health conditions Ensure coordinated care between diabetes/obesity services and mental health teams when appropriate It is essential to recognise that GLP-1 agonists are not a substitute for evidence-based depression treatments, including psychological therapies and antidepressant medications when indicated
